Format

Send to

Choose Destination
Parkinsonism Relat Disord. 2007 Apr;13(3):165-9. Epub 2006 Oct 19.

Calcium channel blockers and beta-blockers in relation to Parkinson's disease.

Author information

1
Department of Epidemiology, University of Washington, Box 357236, Seattle, WA 98195-7326, USA. thanhton@u.washington.edu

Abstract

We investigated the risk of Parkinson's disease (PD) associated with calcium channel blockers (CCBs) and beta-blockers in a population-based case-control study of 206 men and women between ages 35 and 89 with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 controls without PD or other neurodegenerative disorders who were frequency matched on age, sex, duration of GHC enrollment and clinic. The adjusted odds ratio associated with ever use was 0.85 (95% confidence interval [CI]: 0.43, 1.66) for CCBs, and 1.20 (95% CI: 0.71, 2.03) for beta-blockers. We observed no association with PD risk for either class of medication in terms of duration, dose, number of prescriptions or pattern of use. The weakness of these associations and the absence of additional influence of dose or duration of use argue against any causal interpretation.

PMID:
17055323
PMCID:
PMC1893113
DOI:
10.1016/j.parkreldis.2006.08.011
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center